Group 1 - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds [1][2] - The transaction is expected not to constitute a major asset reorganization but is classified as a related party transaction, which does not qualify as a reorganization listing [1] - The company has been actively promoting the transaction since the disclosure of the preliminary plan, and is currently cooperating with intermediaries to conduct due diligence, auditing, and evaluation [2][3] Group 2 - The company’s stock was suspended from trading on May 22, 2025, due to the planning of this transaction, and resumed trading on June 6, 2025 [2] - The board of directors and the supervisory board have approved the transaction plan and its summary during meetings held on June 5, 2025 [2] - The company will adhere to relevant laws and regulations regarding major asset restructuring and will fulfill its information disclosure obligations in a timely manner [3][4]
迈普医学: 关于发行股份及支付现金购买资产并募集配套资金暨关联交易事项的进展公告